Cargando…

Strong reduction of AGO2 expression in melanoma and cellular consequences

BACKGROUND: Processing of microRNAs (miRNAs) is a highly controlled process. Deregulation of miRNA expression was observed in several types of cancer but changes in the miRNA-processing enzymes have not been analysed until today. In this study, we analysed Argonaute2 (AGO2, EIF2C2), as one main fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Völler, D, Reinders, J, Meister, G, Bosserhoff, A-K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859937/
https://www.ncbi.nlm.nih.gov/pubmed/24169347
http://dx.doi.org/10.1038/bjc.2013.646
_version_ 1782295473596399616
author Völler, D
Reinders, J
Meister, G
Bosserhoff, A-K
author_facet Völler, D
Reinders, J
Meister, G
Bosserhoff, A-K
author_sort Völler, D
collection PubMed
description BACKGROUND: Processing of microRNAs (miRNAs) is a highly controlled process. Deregulation of miRNA expression was observed in several types of cancer but changes in the miRNA-processing enzymes have not been analysed until today. In this study, we analysed Argonaute2 (AGO2, EIF2C2), as one main factor of the miRNA processing ensemble, in the context of cancer development, especially in melanoma. METHODS: We determined the AGO2 expression level in melanoma, as well as in other cancers, with biochemical approaches (qRT–PCR, western blot and immunofluorescence studies) and analysed the cell behaviour in migration assays. RESULTS: Specifically in melanoma, we revealed a strong reduction of AGO2 expression compared with primary melanocytes. The reduction of AGO2 expression was only found on protein level, whereas the mRNA level stayed unchanged hinting to post-transcriptional regulation. We could show that re-expression of AGO2 in melanoma leads to a strong improvement of regulatory effects due to increased functionality of small-interfering RNAs and short hairpin RNAs. CONCLUSION: We identified melanoma-specific downregulation of AGO2 and corresponding reduced RNAi efficiency. These findings will help to understand the molecular basis of malignant melanoma and can potentially lead to an improvement of therapeutic strategies.
format Online
Article
Text
id pubmed-3859937
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38599372014-12-10 Strong reduction of AGO2 expression in melanoma and cellular consequences Völler, D Reinders, J Meister, G Bosserhoff, A-K Br J Cancer Genetics and Genomics BACKGROUND: Processing of microRNAs (miRNAs) is a highly controlled process. Deregulation of miRNA expression was observed in several types of cancer but changes in the miRNA-processing enzymes have not been analysed until today. In this study, we analysed Argonaute2 (AGO2, EIF2C2), as one main factor of the miRNA processing ensemble, in the context of cancer development, especially in melanoma. METHODS: We determined the AGO2 expression level in melanoma, as well as in other cancers, with biochemical approaches (qRT–PCR, western blot and immunofluorescence studies) and analysed the cell behaviour in migration assays. RESULTS: Specifically in melanoma, we revealed a strong reduction of AGO2 expression compared with primary melanocytes. The reduction of AGO2 expression was only found on protein level, whereas the mRNA level stayed unchanged hinting to post-transcriptional regulation. We could show that re-expression of AGO2 in melanoma leads to a strong improvement of regulatory effects due to increased functionality of small-interfering RNAs and short hairpin RNAs. CONCLUSION: We identified melanoma-specific downregulation of AGO2 and corresponding reduced RNAi efficiency. These findings will help to understand the molecular basis of malignant melanoma and can potentially lead to an improvement of therapeutic strategies. Nature Publishing Group 2013-12-10 2013-10-29 /pmc/articles/PMC3859937/ /pubmed/24169347 http://dx.doi.org/10.1038/bjc.2013.646 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Genetics and Genomics
Völler, D
Reinders, J
Meister, G
Bosserhoff, A-K
Strong reduction of AGO2 expression in melanoma and cellular consequences
title Strong reduction of AGO2 expression in melanoma and cellular consequences
title_full Strong reduction of AGO2 expression in melanoma and cellular consequences
title_fullStr Strong reduction of AGO2 expression in melanoma and cellular consequences
title_full_unstemmed Strong reduction of AGO2 expression in melanoma and cellular consequences
title_short Strong reduction of AGO2 expression in melanoma and cellular consequences
title_sort strong reduction of ago2 expression in melanoma and cellular consequences
topic Genetics and Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859937/
https://www.ncbi.nlm.nih.gov/pubmed/24169347
http://dx.doi.org/10.1038/bjc.2013.646
work_keys_str_mv AT vollerd strongreductionofago2expressioninmelanomaandcellularconsequences
AT reindersj strongreductionofago2expressioninmelanomaandcellularconsequences
AT meisterg strongreductionofago2expressioninmelanomaandcellularconsequences
AT bosserhoffak strongreductionofago2expressioninmelanomaandcellularconsequences